SPOTLIGHT: Celtic, Inspiration strike collaboration

Celtic Pharma and Inspiration Biopharmaceuticals announced a collaboration--valued at up to $35 million--intended to enhance the development of Inspiration's Factor IX for the treatment of Hemophilia B. Release

Suggested Articles

Paragon Biosciences has hired Kerensa Jimenez as the new CEO of its capital markets group Paragon Health Capital.

Regeneron has taken a step closer to getting a green light for its experimental high cholesterol drug as the FDA allows a swift review of evicanumab.

An analysis of Gilead’s remdesivir clinical trials found the studies “failed to provide equal representation of Black, Latinx and Native Americas."